PM answer
Wait for proof; the easy re-rating may already have happened.
Torex is credible as a recovery watchlist name: FY2026 returned to growth and profitability, management guided FY2027 sales up 11.7%, and the FY2026-2030 plan targets a move from 4.3% operating margin in FY2026 to 12.5% by FY2030. The problem is valuation timing. At JPY 2,440, the stock trades at 18.5x FY2027 guided EPS and 22.5x FY2027 guided operating profit. That is not obviously cheap for a business that has only one year of post-downturn proof.
Decision hinge: can Torex convert a cyclical recovery into structurally higher margins through higher-value power ICs, Phenitec power/device manufacturing, cost control, and the TVS packaging transfer? If not, the current price is vulnerable to mean reversion after a strong recent stock move.
What must be true
- FY2027 revenue guidance must be conservative rather than a one-year restocking bounce.
- Gross margin and SG&A leverage must keep improving without relying mainly on FX tailwinds.
- Phenitec must prove utilization and product mix recovery, especially automotive/power-device demand.
- The TVS transfer must simplify the model without disrupting supply or hiding margin pressure.
- The stock needs earnings revisions or proof of the FY2030 plan; a broad analog-cycle narrative is not enough.
Thesis evidence
A real recovery, but still a proof-of-execution story.
Supported positives
- FY2026 net sales rose to JPY 25.07bn and operating profit recovered to JPY 1.09bn from a FY2025 operating loss.
- Management's FY2027 guide calls for JPY 28.0bn sales, JPY 1.3bn operating profit, JPY 1.4bn net income, and JPY 132.17 EPS.
- The FY2026-2030 plan targets JPY 36.0bn sales and JPY 4.5bn operating profit by FY2030.
- Management is exiting 95% of TVS, the Vietnam post-process subsidiary, to concentrate resources on wafer design and wafer manufacturing processes.
Key challenges
- FY2027 operating margin guidance is only 4.6%, so the FY2030 plan requires most margin expansion after FY2027.
- FY2026 profit was helped by FX and inventory/cost actions; the durability of operating leverage is unproven.
- Public consensus and peer valuation coverage are thin, limiting target-price confidence.
- Stock momentum is strong; recent price strength may have already capitalized the first leg of recovery.
Source notes: FY2026 results and FY2027 guidance are company disclosures. Stock and market values are market data or model-derived from sourced shares, quote, cash, and debt inputs.
Variant perception
What the market may be missing
The positive variant case is not just "semiconductor recovery." It is that Torex becomes a cleaner high-value power-management and power-device compounder after the TVS transfer, while Phenitec and Torex both recover enough volume to spread fixed costs. The negative variant case is that FY2027 is a low-margin rebound, and the FY2030 plan embeds margin expansion that is too back-end loaded for the current multiple.
Business and model
The operating model is simple, but the profit bridge is not.
Torex develops, manufactures, and sells analog integrated circuit products, with main products including DC/DC converters, regulators, detectors, and discrete devices. The company reports a semiconductor-device business with geographic segment disclosure across Japan, Asia, Europe, and North America.
Within Torex parent application sales in FY2026, industrial equipment was the largest specified use case at 38.7% of sales, automotive was 12.9%, medical was 3.8%, wearables were 3.2%, and other applications were 41.4%. For Phenitec, automotive was more material at 32.3% of FY2026 application sales, with other applications at 44.9%.
FY2026 Torex parent application mix, company earnings presentation.
Financial bridge
Management's plan requires operating profit to compound much faster than sales.
| JPY mn unless noted | FY2025A | FY2026A | FY2027E company | FY2028 plan | FY2030 plan |
|---|---|---|---|---|---|
| Net sales | 23,957 | 25,073 | 28,000 | 32,000 | 36,000 |
| Operating profit | (632) | 1,085 | 1,300 | 2,500 | 4,500 |
| Operating margin | -2.6% | 4.3% | 4.6% | 7.8% | 12.5% |
| Net income attributable to parent | (2,358) | 1,159 | 1,400 | n/a | n/a |
| EPS (JPY) | (214.62) | 109.38 | 132.17 | n/a | n/a |
| Capex | 2,950 | 2,273 | 1,600 | n/a | n/a |
FY2025/FY2026 actuals from the FY2026 results release and earnings presentation. FY2027E is company guidance. FY2028/FY2030 are company medium-term plan targets. FY2026 to FY2030 requires about 9.5% sales CAGR and 42.7% operating-profit CAGR.
Valuation gate
The stock is only cheap on FY2030 delivery.
Using the latest verified quote of JPY 2,440, 10.592m net shares, FY2026 cash and deposits of JPY 9.63bn, and interest-bearing debt including lease liabilities of JPY 13.04bn, Torex has a model-derived market cap of JPY 25.85bn and enterprise value of JPY 29.25bn. That is 1.04x FY2027 guided sales and 22.5x FY2027 guided operating profit.
The long-term bull case is visible: if the company hits JPY 4.5bn of operating profit in FY2030 and net debt is stable, today's EV is only 6.5x FY2030 operating profit. But that is four years out and depends on operating margin nearly tripling from FY2026. I would not use a formal target price until there is a sourced peer comp set and at least two more quarters showing margin and order quality.
Target-price status: not assigned. Public third-party data shows a consensus target around JPY 2,950, but visible underlying assumptions are limited, so it is treated as low-confidence context rather than an underwriting anchor.
Capital stack
| Net shares | 10.592m |
| Market cap | JPY 25.85bn |
| Cash and deposits | JPY 9.63bn |
| Debt incl. leases | JPY 13.04bn |
| Net debt | JPY 3.41bn |
| Enterprise value | JPY 29.25bn |
Market cap and EV are model-derived from Yahoo quote and company FY2026 balance sheet data.
Sensitivity - illustrative, not a target price
The valuation debate is about FY2030 multiple and credibility.
Assumption set: FY2030 operating profit of JPY 4.5bn, current net debt held flat, 10.592m net shares. This is a coarse valuation lens, not an analyst target. A near-term EPS multiple lens gives JPY 1,850 at 14x FY2027 EPS, JPY 2,380 at 18x, and JPY 2,910 at 22x.
Catalysts and monitoring
What would change the view
| Monitor | Positive evidence | Negative evidence |
|---|---|---|
| FY2027 quarterly sales | Orders and sales tracking above the JPY 28.0bn guide without large inventory rebuild signals. | Growth fades after restocking, or Q1/Q2 run-rate misses the plan. |
| Gross margin and SG&A | Operating leverage expands even when FX is neutral or less favorable. | Profit guide depends mainly on FX, one-offs, or inventory valuation reversal. |
| Phenitec utilization and mix | Automotive/power-device demand improves and factory utilization drives margin. | Power-device recovery remains too slow to absorb fixed costs. |
| TVS transfer | Transaction closes cleanly, proceeds/gain are transparent, and supply continuity is preserved. | Deconsolidation clouds comparability or causes supply-chain friction. |
| Capital allocation | DOE target supports a floor while growth capex remains disciplined. | Debt stays elevated or capex rises before returns are visible. |
Near calendar
- June 24, 2026: scheduled annual general meeting.
- June 25, 2026: scheduled FY2026 year-end dividend payment.
- August 2026: usual 1Q result window per IR calendar; Stockopedia flags Q1 FY2027 release on August 14, 2026.
- September 29, 2026: Stockopedia flags interim dividend event of JPY 28.00.
Risks and disconfirmers
The downside mechanism is multiple compression if FY2030 credibility weakens.
- FX exposure: Torex discloses overseas sales around 70% of group sales and says sharp moves beyond expectations can affect results.
- Price pressure: management highlights semiconductor industry price volatility, customer price-down requests, and competitive pressure as core risks.
- Cycle and inventory: the FY2026 recovery came after inventory adjustments; another inventory correction would hit both sales and utilization.
- Human capital: analog power IC design is talent-dependent and training takes time, creating execution risk if engineers cannot be hired or retained.
- Transaction execution: the TVS transfer should focus resources, but it also changes the manufacturing footprint and reported comparability.
- Small-cap liquidity: liquidity improved enough to meet Prime Market criteria, but the stock remains a small-cap name with potentially higher gap risk.
Falsifiers
- FY2027 operating margin fails to improve beyond the guided 4.6% despite higher sales.
- Gross margin slips while revenue grows, implying low-quality recovery.
- FY2028 plan bridge is revised down or delayed before FY2027 evidence builds.
- Net debt rises or cash conversion deteriorates while capex continues.
- Management cannot explain the post-TVS margin and supply-chain model clearly.
Evidence and source register
Source discipline and unresolved items
| ID | Source | Use in report | Reliability | Limits |
|---|---|---|---|---|
| S1 | FY2026 consolidated financial results | FY2026 sales, profit, EPS, balance sheet, cash flow, shares, dividends, FY2027 summary guidance. | High | Translated excerpt; Japanese original prevails. |
| S2 | FY2026 full-year earnings presentation | Application mix, regional mix, capex/depreciation, FY2027 guide detail, dividend policy. | High | Japanese presentation; values checked against result release where possible. |
| S3 | FY2026-2030 medium-term plan page | FY2028 and FY2030 sales/operating-profit targets and shareholder return policy. | High | Plan targets, not forecasts with quarterly bridge. |
| S4 | TVS equity transfer notice | 95% TVS transfer, strategic rationale, TVS financial history, expected deconsolidation. | High | Final closing economics still need follow-up disclosure. |
| S5 | Company risk factors | FX, price pressure, human capital, disaster/supply-chain, IP risk framing. | High | Japanese source page. |
| S6 | Yahoo Finance chart endpoint and Yahoo Finance quote page | Current price, volume, quote timestamp, 52-week range. | Medium | Intraday market data can change; fetched June 9, 2026, 09:58 JST. |
| S7 | Stockopedia public quote and profile | Cross-check shares in issue, prior close market cap/EV, public target-price context, upcoming event flags. | Medium | Some details are paywalled/blurred; target-price assumptions are not visible. |
| S8 | Continued listing criteria notice | Liquidity/listing compliance context. | High | As of July 31, 2025; monitor if trading value deteriorates. |
Unresolved evidence requests: proper peer comp set for Japanese analog/power semiconductor peers; current broker consensus and revision history from a licensed provider; ownership/short-interest/borrow data; post-TVS pro forma revenue, margin, cash, and net debt bridge; management commentary from the FY2026 briefing transcript if available.
Final posture
Evidence confidence and underwriting status
Evidence confidence: medium. Reported historicals, guidance, balance sheet inputs, and company strategy are well-sourced. Market data is current but intraday. Consensus and ownership data are incomplete.
Underwriting status: preliminary initiation / watchlist. The report supports continued diligence, not a completed ownership recommendation or formal target price.
Major assumptions: market cap uses net shares outstanding of 10,592,237; EV uses FY2026 cash and deposits plus borrowings and lease liabilities; sensitivity assumes current net debt remains flat; no tax-adjusted DCF or peer multiple set has been built.
Recommended next handoff: equity-model-update for a proper three-statement bridge and peer comp table, followed by thesis-tracker after Q1 FY2027 results.